Flutafarm Femina (flutamide) tablets 0.125 g. №50


Manufacturer: Ukraine

Treatment of locally advanced or metastatic prostate cancer as a means of monotherapy (with or without orchiectomy) or in combination with luteinizing hormone releasing hormone (lgrg) agonists in patients who have not previously been prescribed any treatment, or treatment of patients who do not respond or who have developed resistance to or intolerance to hormone therapy in order to achieve maximum androgen blockade. In combination therapy – as one of the means for the treatment of locally limited prostate cancer B2-C2 (T2B-T4), to reduce the volume of the tumor, strengthen control over the tumor and increase the period between exacerbations of the disease.



Flutafarm Femina Storage
active substance: flutamide;

1 tablet contains flutamide in terms of 100% of the substance – 125 mg (0.125 g);

Excipients: potato starch, lactose monohydrate, colloidal anhydrous silica, calcium stearate.

Flutafarm Femina Dosage form

Basic physical and chemical properties: tablets of light yellow color, with a flat surface, with a line on one side and a facet.

Flutafarm Femina Pharmacotherapeutic group
Hormone antagonists and similar drugs. Antiandrogenic drugs. ATX code L02B B01.

Pharmacological properties


Flutapharm® Femina is a non-steroidal drug with antiandrogenic action.

In women with hyperandrogenic conditions accompanied by infertility and ovarian-menstrual disorders (eg, scleropolycystic ovary syndrome), Flutapharm® Femina blocks the pathogenic effects of endogenous androgens on the ovaries and other reproductive organs, as well as on the hypophyte. Due to this, patients have reduced symptoms of hyperandrogenism (hirsutism), menstruation is restored, folliculogenesis and menstrual cycle are improved, which probably leads to the restoration of fertility in some patients.


Flutamide is well absorbed from the digestive tract. The maximum concentration in the blood is observed 2 hours after oral administration. It is rapidly metabolized with the formation of the active metabolite – 2-hydroxyflutamide and other substances. The half-life of the active metabolite is 5 – 6 hours. It is eliminated mainly with urine. In 2 days 91% is excreted from the body, in 3 days – 98% of the administered dose.

Treatment of women with functional hyperandrogenism, which is accompanied by disorders of the ovarian-menstrual cycle, hirsutism, scleropolycystic ovary syndrome and infertility.

Hypersensitivity to flutamide or to other components of the drug. Hyperandrogenism of organic origin (tumors of the ovaries and adrenal cortex). Severe hepatic impairment (baseline liver enzymes should be assessed prior to treatment).

Children’s age.